• A
  • A
  • A
  • ABC
  • ABC
  • ABC
  • А
  • А
  • А
  • А
  • А
Regular version of the site

News, November 18, 2020

Page 1 of 1
2020, August
1Sa2Su3Mo4Tu5We6Th7Fr8Sa9Su10Mo11Tu12We13Th14Fr15Sa16Su17Mo18Tu19We20Th21Fr22Sa23Su24Mo25Tu26We27Th28Fr29Sa30Su31Mo
2020, November
1Su2Mo3Tu4We5Th6Fr7Sa8Su9Mo10Tu11We12Th13Fr14Sa15Su16Mo17Tu18We19Th20Fr21Sa22Su23Mo24Tu25We26Th27Fr28Sa29Su30Mo
2021, January
1Fr2Sa3Su4Mo5Tu6We7Th8Fr9Sa10Su11Mo12Tu13We14Th15Fr16Sa17Su18Mo19Tu20We21Th22Fr23Sa24Su25Mo26Tu27We28Th29Fr30Sa31Su
2021, February
1Mo2Tu3We4Th5Fr6Sa7Su8Mo9Tu10We11Th12Fr13Sa14Su15Mo16Tu17We18Th19Fr20Sa21Su22Mo23Tu24We25Th26Fr27Sa28Su
2021, May
1Sa2Su3Mo4Tu5We6Th7Fr8Sa9Su10Mo11Tu12We13Th14Fr15Sa16Su17Mo18Tu19We20Th21Fr22Sa23Su24Mo25Tu26We27Th28Fr29Sa30Su31Mo
Illustration for news: ‘A Completely New Platform, Never Studied or Used Before’: mRNA by Pfizer vs. Sputnik V Viral Vectors

‘A Completely New Platform, Never Studied or Used Before’: mRNA by Pfizer vs. Sputnik V Viral Vectors

One of the biggest headlines of recent days has been the announcement made by Pfizer, a U.S.-based company, and BioNTech, Germany, that BNT162b2, a COVID-19 vaccine they are developing, has proved to be 90% effective in its Phase 3 clinical trial. The news was met with big excitement all over the world. However, the Pfizer-BioNTech vaccine is based on a new platform, which is still understudied. According to protocol, its trial will be complete only in 2022. IQ talked to Larisa Popovich, Director of the HSE Institute for Health Economics, about the differences between the U.S.-German and the Russian Sputnik V vaccines, and about the chances of beating COVID-19 with massive immunization in the upcoming months.